Logo

Organon Signs Toxicogenomics Service Deal with Gene Logic

Jul 28, 2004

NEW YORK, July 28 (GenomeWeb News) - Gene Logic has signed a toxicogenomics services deal with Organon, the companies said today.

 

Under the eighteen-month deal, GeneLogic will provide ToxScreen and Mechanism of Toxicity reports to Organon in order to evaluate the safety and toxicity of its drug candidates. The  companies did not disclose the financial terms of the deal.

 

Organon has been a subscriber to Gene Logic's GeneExpress database since December 2000.

Breaking News
The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.